Table 1.
Baseline demographics and immune markers.
| Pitavastatin N = 111 | Pravastatin N = 114 | |
|---|---|---|
| Age | 50.0 ± 7.6 | 49.1 ± 8.4 |
| Sex, % female | 14 (16/111) | 11 (12/114) |
| Race | ||
| White % | 85 (94/111) | 76 (87/114) |
| Black % | 12 (14/111) | 19 (21/114) |
| Asian % | 1 (1/111) | 1 (1/114) |
| Other % | 2 (2/111) | 4 (4/114) |
| Hispanic % | 24 (27/111) | 28 (32/114) |
| Hepatitis B/C | 8 (9/111) | 11 (12/114) |
| eGFR (ml/min/1.73m2) | 80 ± 16 | 81 ± 16 |
| Total Cholesterol (mg/dl) | 239 ± 32 | 238 ± 31 |
| HDL-C (mg/dl) | 49 ± 15 | 49 ± 12 |
| LDL-C (mg/dl) | 156 ± 27 | 154 ± 24 |
| Triglycerides (mg/dl) | 177 ± 95 | 169 ± 70 |
| BMI (kg/m2) | 27.4 ± 4.6 | 28.3 ± 5.0 |
| Framingham Risk Score % | 6.7 ± 5.1 | 6.3 ± 4.7 |
| Log HIV-1 Viral Load (copies/ml) | 1.1 ± 0.3 | 1.1 ± 0.2 |
| CD4 count (cells/mm3)⁎ | 663 ± 264 | 576 ± 212 |
| sCD163 (ng/ml) | 1114 ± 567 | 1006 ± 393 |
| hsIL-6 (pg/ml) | 1.7 ± 2.8 | 1.7 ± 2.3 |
| MCP-1 (pg/ml) | 158.7 ± 67.0 | 151.8 ± 67.8 |
| sCD14 (ng/ml) | 2085 ± 1285 | 1893 ± 1031 |
| oxLDL (U/l) | 78.3 ± 21.9 | 77.8 ± 18.9 |
| Lp-PLA-2 (ng/ml) | 193.8 ± 61.6 | 186.9 ± 71.7 |
| hsCRP (mg/dl) | 4.3 ± 8.7 | 5.5 ± 14.8 |
Normally distributed data are reported as mean ± standard deviation.
No significant differences between baseline values unless indicated.
Abbreviations: eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; BMI, body mass index; HIV-1, Human Immunodeficiency Virus-1; sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6, MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2; hs-CRP, high sensitivity c-reactive protein.
⁎
P-Value = 0.008